Gilenya, Novartis's new oral medication-from the CCSVI perspective
Viewing Gilenya from the CCSVI perspective written for CCSVI Alliance by Al Ossorio   While CCSVI treatment is quite different from pharmaceutical treatment for MS, in some cases they do share common scientific assumptions and pragmatic goals....